The Hippo pathway effectors TAZ and YAP are sequentially required in lung development.

H. Isago (Tokyo, Japan), A. Mitani (Tokyo, Japan), S. Kohno (Tokyo, Japan), H. Nagoshi (Tokyo, Japan), T. Ishimori (Tokyo, Japan), M. Saito (Tokyo, Japan), H. Tamiya (Tokyo, Japan), Y. Mikami (Tokyo, Japan), M. Horie (Tokyo, Japan), H. Urushiyama (Tokyo, Japan), T. Jo (Tokyo, Japan), G. Tanaka (Tokyo, Japan), R. Hamamoto (Tokyo, Japan), Y. Terasaki (Tokyo, Japan), T. Nagase (Tokyo, Japan)

Source: International Congress 2019 – Molecular and experimental paediatric lung disease
Session: Molecular and experimental paediatric lung disease
Session type: Oral Presentation
Number: 3604

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Isago (Tokyo, Japan), A. Mitani (Tokyo, Japan), S. Kohno (Tokyo, Japan), H. Nagoshi (Tokyo, Japan), T. Ishimori (Tokyo, Japan), M. Saito (Tokyo, Japan), H. Tamiya (Tokyo, Japan), Y. Mikami (Tokyo, Japan), M. Horie (Tokyo, Japan), H. Urushiyama (Tokyo, Japan), T. Jo (Tokyo, Japan), G. Tanaka (Tokyo, Japan), R. Hamamoto (Tokyo, Japan), Y. Terasaki (Tokyo, Japan), T. Nagase (Tokyo, Japan). The Hippo pathway effectors TAZ and YAP are sequentially required in lung development.. 3604

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: